Pharmacodynamics of levodopa in Parkinson's disease
- PMID:8593740
- DOI: 10.1111/j.1440-1681.1995.tb01946.x
Pharmacodynamics of levodopa in Parkinson's disease
Abstract
1. Levodopa markedly reduces parkinsonism during the first years of treatment. However, with continued therapy the response to levodopa becomes erratic and is complicated by involuntary movements. To improve the therapy of parkinsonism, the challenge is to understand why fluctuations in response develop and, once developed, what controls the moment to moment motor status. 2. In patients with a fluctuating response to levodopa, three distinct responses can be recognized: a short-duration response, a long-duration response and a negative response. 3. The short-duration response, measured in minutes to hours, has a steep concentration-response relationship such that the response appears 'all or nothing.' The duration of effect is dose-responsive. The short-duration response becomes shorter during chronic therapy, possibly because of tolerance. The onset to effect becomes briefer and the magnitude of the response becomes larger during chronic therapy, possibly because of sensitization. 4. The long-duration response, measured in days to weeks, develops and decays slowly. The rate of decay is proportional to the severity of the parkinsonism and therefore this response may relate to dopamine storage capacity of remaining nerve terminals. 5. The negative response, measured in minutes, is a worsening of motor function as the short-duration improvement wears off. It may reflect a biphasic concentration-response relationship. 6. The response to levodopa in parkinsonian patients is a complex interplay between responses with different time courses and variably affected by sensitization, tolerance and disease progression.
Similar articles
- Concentration-effect relationship of levodopa in patients with Parkinson's disease.Harder S, Baas H, Rietbrock S.Harder S, et al.Clin Pharmacokinet. 1995 Oct;29(4):243-56. doi: 10.2165/00003088-199529040-00004.Clin Pharmacokinet. 1995.PMID:8549026Review.
- Motor fluctuations in levodopa treatment: clinical pharmacology.Stocchi F, Bonamartini A, Vacca L, Ruggieri S.Stocchi F, et al.Eur Neurol. 1996;36 Suppl 1:38-42. doi: 10.1159/000118882.Eur Neurol. 1996.PMID:8791020Review.
- Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.Harder S, Baas H.Harder S, et al.Clin Pharmacol Ther. 1998 Aug;64(2):183-91. doi: 10.1016/S0009-9236(98)90152-7.Clin Pharmacol Ther. 1998.PMID:9728899
- Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.LeWitt PA.LeWitt PA.Mov Disord. 2015 Jan;30(1):64-72. doi: 10.1002/mds.26082. Epub 2014 Dec 1.Mov Disord. 2015.PMID:25449210Review.
- Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ.Colosimo C, et al.J Neurol Neurosurg Psychiatry. 1996 Jun;60(6):634-7. doi: 10.1136/jnnp.60.6.634.J Neurol Neurosurg Psychiatry. 1996.PMID:8648329Free PMC article.
Cited by
- An objective fluctuation score for Parkinson's disease.Horne MK, McGregor S, Bergquist F.Horne MK, et al.PLoS One. 2015 Apr 30;10(4):e0124522. doi: 10.1371/journal.pone.0124522. eCollection 2015.PLoS One. 2015.PMID:25928634Free PMC article.
- A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.Evans AH, Kettlewell J, McGregor S, Kotschet K, Griffiths RI, Horne M.Evans AH, et al.PLoS One. 2014 Feb 24;9(2):e89319. doi: 10.1371/journal.pone.0089319. eCollection 2014.PLoS One. 2014.PMID:24586685Free PMC article.
- COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.Antonini A, Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Onofrj M, Zappia M, Quattrone A.Antonini A, et al.Neuropsychiatr Dis Treat. 2008 Feb;4(1):1-9. doi: 10.2147/ndt.s2404.Neuropsychiatr Dis Treat. 2008.PMID:18728767Free PMC article.
- Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.Dodel RC, Berger K, Oertel WH.Dodel RC, et al.Pharmacoeconomics. 2001;19(10):1013-38. doi: 10.2165/00019053-200119100-00004.Pharmacoeconomics. 2001.PMID:11735671Review.
- Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ.Katzenschlager R, et al.J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7. doi: 10.1136/jnnp.2003.028761.J Neurol Neurosurg Psychiatry. 2004.PMID:15548480Free PMC article.Clinical Trial.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical